Apimeds shares surge 32.42% after hours on AI biotech partnerships and FDA draft guidance optimism.

Apimeds surged 32.42% in after-hours trading following announcements of expanding its AI-driven biotech collaborations with the University of Idaho, University of Oregon, and University of San Diego, as well as regulatory optimism tied to the FDA’s draft guidance on non-opioid pain programs. The stock’s sharp rise reflects investor optimism about these strategic partnerships and potential regulatory progress for its Apitox pipeline, despite concerns over $5.1 million in cash burn and a -5.68 dynamic PE. The move aligns with the company’s focus on integrating academic talent into innovation-driven biotech initiatives, positioning it as a potential leader in AI-focused pharmaceutical development.